Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages ...

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average recommendation of “Hold” from the ...

Short interest in CARISMA Therapeutics Inc (NASDAQ:CARM) decreased during the last reporting period, falling from 537.68K to 437.88K. This put 1.31% of the company's publicly available shares short.

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Monday,Benzinga reports.

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today ...

Carisma Therapeutics Inc. has entered into a master services agreement with Danforth Global, Inc. and Danforth Advisors, LLC to receive finance and accounting services from Natalie McAndrew ...

Despite the notice, Carisma Therapeutics' stock will continue to be traded on The Nasdaq Global Market under the ticker symbol "CARM." Carisma Therapeutics has been granted a 180-day period, ending on ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced that Steven Kelly, President and Chief Executive ...